Silvaneus's channel

Paul B. Chapman, MD, from Memorial Sloan-Kettering Cancer Center, describes the most common side effects of the drug vemurafenib (Zelboraf), which ...

Sandhya Pruthi, MD, associate professor of medicine at the Mayo Clinic in Rochester, Minnesota, discusses other options to help control hot flashes...

Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb, elaborates on the trial comparing ipilimumab (Yervoy) plus dac...

Lead investigator Brian I. Rini, MD, a staff member in the Department of Solid Tumor Oncology at the Taussig Cancer Institute at Cleveland Clinic i...

Allen S. Lichter, MD, the chief executive officer of the American Society of Clinical Oncology (ASCO) feels that in many respects ASCO is the world...

H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington discusses some of the re...

Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb discusses the need to understand the clinical kinetics of immun...

Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, describes the genetic mutation screening multic...

Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada discusses cabozantinib's dose size.

Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb on the amount of patients that respond to ipilimumab.

Nicholas J. Vogelzang, MD, Comprehensive Cancer Centers of Nevada Discusses Mortalities in Cabozantinib Trial

Howard Scher, MD, from Memorial Sloan-Kettering Cancer Center discusses circulating tumor cells.

After surviving osteosarcoma, Charlie Lustman recorded the CD Made Me Nuclear, which describes his cancer experience. He then adapted the album int...

Sridhar Ramaswamy, MD, Tucker Gosnell Investigator and Associate Professor of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medic...